

Epigenetic Mechanisms Associated with Progression, Prognosis, and New Treatment Strategies for Metastatic Cervical Squamous Cell Carcinoma: Literature Review

BJosué Mondragón-Morales^{1*}, Rogelio Rogel-Alvarado², Iris Alejandra Noverón-Figueroa¹, Max Morales-Gutierrez³

1

1. Escuela Superior de Medicina, Instituto Politécnico Nacional, Salvador Díaz Mirón esq. Plan de San Luis S/N, Miguel Hidalgo, Casco de Santo Tomás, 11340, México City, México, CP 11340

2. Facultad de Enfermería y Obstetricia, Universidad Nacional Autónoma de México, Camino Viejo a Xochimilco y Viaducto Tlalpan S/N. San Lorenzo Huipulco, Tlalpan. Ciudad de México. C.P. 14370

3. Universidad Westhill, Domingo García Ramos N° 56, Cuajimalpa Col. Prados de la Montaña, Ciudad de México. C.P. 05610

*Corresponding author:
Josué Mondragón-Morales,

e-mail:
jos.mond.m@gmail.com,

Escuela Superior de Medicina, Instituto Politécnico Nacional, Salvador Díaz Mirón esq. Plan de San Luis S/N, Miguel Hidalgo, Casco de Santo Tomás, 11340, México City, México, CP 11340

ABSTRACT

Background: In the 21st century, the main cause of death in both sexes worldwide are cardiovascular diseases, in second place are neoplasms. In the case of women, the fourth cause of mortality is breast cancer, despite the screening. This study aims to understand the epigenetic mechanisms associated with cervical cancer progression and metastasis, considering its correlation with poor prognosis.

Material and Methods: To prepare the present article, the search was done on platforms PubMed and Google Scholar, the search was carried out using the following medical subject headings (MeSH) in the search engine: “metastatic cervical cancer”, “cervical cancer epigenetics”, “cervical cancer genetics”, “cervical cancer mirnas”, “cervical cancer lncrnas”, “cervical cancer clinical trials” and “metastatic cervical cancer hpv”, in combination with boolean connectors ‘AND’ and ‘OR’. A total of 114 articles were reviewed, published between 1989 and 2022.

Results and conclusions: It is essential to understand and know the epigenetic mechanisms associated with cervical cancer pathogenesis and progression, to create new targeted treatment schemes for metastatic cervical cancer to reduce the mortality rate and increase disease-free survival.

Keywords: Metastasis; Cervical Cancer; lncRNA; Clinical trials; Targeted therapy



Copyright © 2024 Tehran University of Medical Sciences. Published by Tehran University of Medical Sciences.

This work is licensed under a creative commons Attribution-nonCommercial 4.0 international license (<https://creativecommons.org/licenses/by-nc/4.0/>).

Non-commercial uses of the work are permitted, provided the original work is properly cited.

INTRODUCTION:

Cervical cancer (CC) is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women after breast, colorectum, and lung cancers. Its incidence has been estimated at 604,000 new cases and its mortality at 342,000 deaths worldwide in 2020 (1). Human Papillomavirus (HPV) persistent infection is a necessary factor, observed in 99% of CC (2); however, it is not sufficient for the progression to cervical cancer (2). The main risk factors associated with CC are socio-demographic (age and education level), lifestyle behavior (diet, personal hygiene, and smoking status (3)), sexual behavior (number of sexual partners, age at sexual debut, and use of contraceptive method), gestational factors (number of pregnancies), and screening (4) and comorbidities (immunosuppressive states (5), such as Human Immunodeficiency Virus (HIV) (6), Diabetes Mellitus (DM), etc. (7,8). However, new evidence has been established as a potential risk, progression, and potential therapeutic targeted factors.

Material and Methods:

To prepare the present article, the search was done on platforms PubMed and Google Scholar, the search was carried out using the following medical subject headings (MeSH) in the search engine: “metastatic cervical cancer”, “cervical cancer epigenetics”, “cervical cancer genetics”, “cervical cancer mirnas”, “cervical cancer lncrnas”, “cervical cancer clinical trials” and “metastatic cervical cancer hpv”, in combination with boolean connectors ‘AND’ and ‘OR’. A total of 114 articles were reviewed, published between 1989 and 2022. Cervical cancer pathogenesis.

Cervical cancer pathogenesis

As is known, HPV persistent infection is necessary for CC, however, it is not sufficient for CC progression. HPVs are double-stranded circular DNA viruses with an icosahedral capsid from the Papillomaviridae family. HPVs can be subdivided classically in low and high-risk HPVs depending on their association between viral genome integration (9) and anogenital cancer (10). New evidence indicates that epigenetic and genetic alterations act synergistically with HPV proteins for carcinogenesis. DNA damage is necessary for the addition of mutations; however, aberrant histone modifications can be associated with this type of cancer.

DNA is coiled around by histones to form nucleosomes, the basic unit of chromosomes. The alteration of its function leads to prolonged DNA damage (11).

The association between specific HPVs and anogenital cancer has been strongly established. The DNA of certain high-risk HPVs, such as HPV-16, 18, 31, 33, and 39 is found in about 85% of cervical squamous cell carcinomas (CSCC) (12,13). HPV genome can be classified into three important regions: a coding region that contains early genes, E1, E2, E4, E5, E6 and E7; a region that contains genes that encode capsid proteins L1 and L2; and a non-coding region (10). HPV E6 and E7 genes are regularly expressed in HPV positive CSCC, whose are necessary for immortalization of CSCC by the interaction with tumor suppressor gene products (14). The interaction between HPV E6 protein -p53 in presence of an active ubiquitin proteolysis system leads to the specific degradation of p53 (15,16), in other words, the active degradation of negative regulator of cell growth (14). In addition, HPV E6 protein interacts with DNA methyltransferase 1 (DNMT1) (17,18), which is responsible of the methylation of cyclin A1 (CCNA1), a regulatory protein necessary for the development of CSCC (19).

The HPV E7 protein can form a specific complex with the retinoblastoma tumor suppressor gene product (p105-RB) (20), disrupting in the negative regulation of cellular growth and differentiation (21); and inhibits the activity of DNMT gene that encodes for E-cadherin protein (22) and CCL20 secretion (23) in Langerhans cells (24), its reduction may affect the efficiency by which the immune system responds to length of persistent HPV infection (25). In addition, HPV E7 protein activates the enhancer of zeste homologue 2 gene (EZH2), which encodes a polycomb group protein that interacts as a histone methyltransferase (26,27) with the regulatory function of HPV positive cancers (28) by the control of cell proliferation and it contributes to apoptotic resistance (29). The high levels of the trimethylation of lysine 27 on histone H3 (H3K27me3) by EZH2, as part of the polycomb repressive complex 2 (PRC2) contributes to progression of carcinogenesis. Another protein included as a component of the polycomb repressive complex 1 (PRC1) known as BMI1 interacts with HPV E7 protein interacting with H3K27me3, however, its specific function is already unknown (30). The demethylation of this epigenetic pathway is regulated by the KDM6A and KDM6B histone 3 lysine 27-specific demethylases, whose

remove H3K27me3 from the p16 INK4A promoter during ras/raf oncogene induced cellular senescence (31). HPV E7 protein can bind and destabilize pRB-E2F repressor complexes, allowing for uncontrolled cell cycle progression (32).

As already known, HPV persistent infection is the causal factor for cervical cancer, and the two most important proteins associated with carcinogenesis are HPV E6 and E7 proteins, whose interact with human cell proteins in gene transcription. However, the regulation of the posttranscriptional regulation is another important step in the regulation of gene transcription. In this step, there are two important epigenetic regulators, the non-coding RNAs (NcRNAs) and the RNA-binding proteins (RBPs) (33).

Cyclin dependent kinase inhibitor 2A (CDKN2A), ELAV like RNA binding protein 2 (ELAVL2), growth factor receptor bound protein 7 (GRB7), heat shock protein family B member 1 (HSPB1), KH-type splicing regulatory protein (KHSRP), polypyrimidine tract binding protein 1 (PTBP1), ribonuclease H2A (RNASEH2A), and neuro-oncological ventral antigen 1 (NOVA1) genes encode RBP proteins, and they are altered in HPV positive cancers, and are associated with the development of cervical cancer (33).

Other genetic alterations observed in CSCC demonstrated by The Cancer Genome Atlas (TCGA) project may lead to understand the signal pathways that may drive to tumorigenesis and serve as a prognostic or therapeutic markers. In cervical cancer, the number of somatic copies alterations are well established, amplification of telomerase RNA component (TERC, 78%), tumor protein p63 (TP63, 77%), MYC proto-oncogene (MYC, 42%), CD274 (programmed cell death 1 ligand, PD-L1, 21%), PDCD1LG2 (programmed cell death 2 ligand, PD-L2, 21%), breast cancer anti-estrogen resistance 4 (BCAR4, 20%), KLF transcription factor 5 (KLF5, 18%), epidermal growth factor receptor (EGFR, 17%), baculoviral IAP repeat containing 2/3 (BIRC2/3, 17%), and erb-b2 receptor tyrosine kinase 2 (ERBB2, 17%); recurrent deletions of transforming growth factor beta receptor 2 (TGFB2, 36%), FAT atypical cadherin 1 (FAT1, 36%), phosphate and tensin homolog (PTEN, 31%), and SMAD family member 4 (SMAD4, 28%) genes, were the most prevalent. (34) The molecular mechanisms, such as DNA mutations, and their respective signaling pathways are observed in CSCC carcinogenesis, as seen in Figure 1, which shows

the upregulation or downregulation of their respective metabolic pathways, and if exists an associated specific targeted therapy.

Epigenetic mechanisms associated with metastasis

Epigenetic mechanisms are associated with multiple metabolic pathways; however, currently new evidence has aroused interest in how such mechanisms are associated with proliferation, invasion, and metastasis in cancer (35). There are some genome regions that do not code for proteins called NcRNAs (36), which can be classified as small non-coding RNAs (sncRNAs) and long non-coding RNAs (lncRNAs) depending on their length (<200 nucleotides and >200 nucleotides, respectively). Among them, the most studied NcRNAs are microRNAs (miRNAs, defined as single-stranded RNAs of approximately 22 nucleotides in length) (37), lncRNAs, circular RNAs (circRNAs, which as their name, they are not linear RNAs, and arise from precursors mRNAs) (38,39), and PIWI interacting RNAs (piRNAs) (40).

The NcRNAs interact with many signaling pathways that involucre cell metabolism, the lncRNA named cervical cancer DExH-box helicase 9 (DHX9) suppressive transcript (abbreviated as lncRNA CCDST) inhibits cell migration, invasion, anchorage-independent growth, and angiogenesis by the degradation of DHX9 protein, a member of DEAH-containing family of RNA helicases, which is responsible of many regulatory mechanisms in relation with cell growth. In CSCC, this lncRNA is downregulated in contrast with normal cervical squamous cells (41), lncRNA UICC is another epigenetic mechanism associated with International Federation of Gynecology and Obstetrics (FIGO) stage, lymph node metastasis and prognosis, however, it interacts via IL-6/STAT3 (42), lncRNA colon cancer associated transcript-1 (CCAT-1) (43), lncRNA DGCR5 interact via Wnt signaling pathway promoting tumor progression (44), and lncRNA CDKN2B-AS1 is upregulated in CC and its function is the regulation of cell proliferation (45). The metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) is another lncRNA, which high levels are associated with CC invasion and metastasis (46–48). Thymopoietin pseudogene 2 (TMPOP2), also named lncRNA-EBIC, was recently reported to highly expressed in CSCC, it interacts with EZH2 to downregulate the expression of E-cadherin (49).




Figure 1. Regulation of the different signaling pathways associated with pathogenesis of cervical squamous cell carcinoma and its relationship with current targeted therapies. Created with Biorender.com

LncRNA in non-homologous end joining (NHEJ) pathway 1 (LINP1) is a lncRNA necessary in DNA repair activity by the interaction with Ku80 and DNA-PKcs, proteins of NHEJ pathway. LINP1 can be a potential therapeutic target and a possible radiotherapy-resistance biomarker (50), as lncRNA urothelial cancer associated 1 (UCA1) (51) and LINC00958 by miRNA-5095 regulates radio-resistance (52). Some lncRNAs interact with miRNAs, by increasing or decreasing its levels, as growth arrest special 5 (GAS5), which binds to miR-196a and miR-205 to downregulate its expression. GAS5 overexpression suppresses CSCC proliferation, and invasion (53,54), lncRNA NOC2L-4.1

is upregulated in CSCC, its function is the inhibition of miR-630/YAP1 pathway, which is associated with CC pathogenesis (55). LncRNA IDH1-AS1 regulates metabolic reprogramming to generate energy through increased glycolysis even in the presence of oxygen (Warburg effect) via c-Myc to collaborate with hypoxia inducible factor 1 α (HIF1 α) (56). Other lncRNAs such as PVT1 can determine chemoresistance by silencing miR-195 (57,58). The high expression of STXBP5-AS1, another lncRNA suppresses the proliferation and invasion by acting as a sponge of miR-96-5p to regulate PTEN expression (59), TP73-AS1 promotes proliferation and invasion via miR-329-3p/ARF1 (60), TUSC8 via

Table 1. Summary of the NcRNAs associated with progression and poor prognosis in metastatic cervical squamous cell carcinoma (mCSCC).

NcRNA	Targeted protein	Oncogenic processes	Tumor expression pattern	Reference
LncRNA CCDST	DHX9 protein DEAH-containing family of RNA helicases	Inhibits cell migration, invasion, anchorage-independent growth, and angiogenesis	Downregulation	(41)
LncRNA UICC	IL-6/STAT3 pathway	Lymph node metastasis and prognosis	Upregulation	(42)
LncRNA CCAT-1	MYC oncoprotein	Metastasis	Upregulation	(43)
LncRNA DGCR5	Wnt signaling pathway	Tumor progression	Upregulation	(44)
LncRNA CDKN2B-AS1	miR-181a-5p TGF- β 1 signaling pathway	Regulation of cell proliferation	Upregulation	(45)
MALAT-1	miR-124, miR-145, miR-202-3p	Tumor invasion and metastasis	Upregulation	(46–48)
TMPOP2 (LncRNA-EBIC)	EZH2 E-cadherin	Metastasis	Upregulation	(49,80)
LINP1	Ku80 DNA-PKcs	Possible radiotherapy-resistance biomarker	Upregulation	(50)
LncRNA UCA1	CREB	Metastasis	Upregulation	(51)
LINC00958	miRNA-5095	Regulates radiotherapy resistance	Upregulation	(52)
GAS5	miR-196a miR-205	Tumor proliferation and Invasion	Downregulation	(53,54)
NOC2L-4.1	miR-630/YAP1 pathway	Proliferation and Invasion	Upregulation	(55)
IDH1-AS1	HIF1 α	Warburg effect	Upregulation	(56)
PVT1	miR-195	Chemoresistance	Upregulation	(57,58)
STXBP5-AS1	miR-96-5p	Proliferation and Invasion	Downregulation	(59)
TP73-AS1	miR-329-3p/ARF1	Proliferation and Invasion	Upregulation	(60)
TUSC8	miR-641/PTEN	Cell growth	Downregulation	(61)
LncRNA XIST	miR-200a miR-200b	Tumor progression	Upregulation	(62,63)
LncRNA XLOC_006390	miR-331-3p miR-338-3p	Tumorigenesis and Metastasis	Upregulation	(64)
LncRNA-CTS	miR-505/ZEB260	Metastasis	Upregulation	(65)
LncRNA ATB/miR-144/ITGA6	SMAD/TGF signaling pathway	Proliferation and Invasion	Upregulation	(66)
LncRNA ANRIL	PI3K/AKT pathway	Carcinogenesis and Poor prognosis	Upregulation	(67)
CRNDE	PUMA	Cell growth	Downregulation	(68)
HOTAIR	STAT3 miR-148a HLA-G	Proliferation, Migration, Invasion, Worse prognosis, and Immunotherapy resistance	Upregulation	(69,70)
MEG3	P-STAT3	Cell growth, Apoptosis and Proliferation	Downregulation	(71)
LncRNA SPRY4-IT1	miR-101-3p/ZEB1	Poor prognosis, Migration, and Invasion	Upregulation	(72)
LncRNA TTN-AS1	miR-573/E2F3	Cell growth, Proliferation, Invasion, and Metastasis	Upregulation	(73)
LncRNA TUG1	miR-138-5p-SIRT1	Cell growth, Proliferation, Invasion, and Metastasis	Upregulation	(74)
lncRNA ZEB1-AS1		Cell growth, Proliferation, Invasion, and Metastasis	Upregulation	(75)

lncRNA LINC01535	miR-214/EZH2	Cell growth, Proliferation, Invasion, and Metastasis	Upregulation	(76)
lncRNA TP73	miRNA-607/cyclin D2	Cell growth, Proliferation, Invasion, and Metastasis	Upregulation	(77)
lncRNA SNHG12	miR-125b/STAT3	Cell growth, Proliferation, Invasion, and Metastasis	Upregulation	(78)
lncRNA ZNF667-AS1	miRNA-93-3p-dependent PEG3 downregulation	Cell growth, Proliferation, Invasion, and Metastasis	Upregulation	(79)
lncRNA XLOC_010588	c-Myc	Cell growth, Proliferation, Invasion, and Metastasis	Upregulation	(81)
miR-221-3p	THBS2	Proliferation, Invasion, Migration, and Angiogenesis	Upregulation	(82)
miR-21	RAS/MAPK signaling	Lymph node metastasis	Downregulation	(83)
miR-665	ERK/SMAD pathway TGFBF1	Cell cycle and drug resistance	Downregulation	(84)
miR-138-5p	LncRNA H19	FIGO stage, poor differentiation, lymph node metastasis, and poor overall survival	Downregulated	(85)
miR-106b	TGF- β -induced cell migration	Cell proliferation, migration, and invasion	Upregulation	(86)
miR-145	SMAD interacting protein 1 (SIP1)	Cell proliferation, migration, and invasion	Upregulation	(87)
miRNA-183		Cell invasion and metastasis	Downregulation	(88)
miR-218-5p	LYN/NF- κ B signaling pathway	Cell growth and metastasis	Downregulation	(89)
miRNA-221-3p	THBS2	Metastasis	Upregulation	(90)
miR-29a	Methylation of tumor suppressor SOCS1	Invasion and metastasis	Downregulation	(91)
miR-124	amotL1	Vasculogenic mimicry, cell motility, endothelial migration, and cell polarity, and to regulate sprouting angiogenesis	Downregulation	(92)
miR-199b-5p	KLK10	Growth and metastasis	Upregulation	(93)
miR-519d	SMAD7 TGF- β signaling	Tumor progression and metastasis	Upregulation	(94)
miR-543	TRPM7	Tumor growth and metastasis	Downregulation	(95)
miRNA-21	TNFR1	lymph node metastasis	Upregulation	(96)
CircRNA-000284	miR-506	Cell proliferation, migration, and invasion	Upregulation	(97)
hsa_circ_0000745	E-cadherin	Cell proliferation, migration, and invasion	Downregulation	(98)

miR-641/PTEN (61), lncRNA XIST via Fus/miR-200a (62) and miR-200b (63), lncRNA XLOC_006390 facilitates CC tumorigenesis and metastasis through competing with miR-331-3p and miR-338-3p (64), lncRNA-CTS promotes metastasis by regulating miR-505/ZEB260 (65) and lncRNA ATB/miR-144/ITGA6 via

SMAD/TGF signaling pathway (66). lncRNA ANRIL promotes carcinogenesis and poor prognosis in CSCC by the regulation of PI3K/AKT pathway (67). As HPV proteins can interact with p53 expression, some lncRNAs such as CRNDE, interacts with p53 upregulated modulator of apoptosis (PUMA) protein,

which is necessary for cell growth (68). Homeobox (HOX) transcript antisense RNA (HOTAIR) is another lncRNA that has been reported to be an important epigenetic mechanism in many types of cancers. HOTAIR upregulation is associated with proliferation, migration and invasion of CSCC, as observed in STAT3 inhibition (69), however, its function is not limited to this pathway, since it has been shown that HOTAIR interacts with miR-148a, which modulates the expression of human leukocyte antigen-G (HLA-G) associating worse prognosis and immunotherapy resistance (70). LncRNA MEG3 inhibits cell growth via ubiquitination and degradation of P-STAT3, in consequence, CC cells lead to apoptosis and the inhibition of proliferation (71). The lncRNA SPRY4-IT1 predicates poor prognosis and promotes tumor progression by regulating the miR-101-3p/ZEB1 which contributes to CC migration and invasion (72). LncRNA TTN-AS1 via miR-573/E2F3 (73), lncRNA TUG1 via miR-138-5p-SIRT1 (74), lncRNA ZEB1-AS1 (75), lncRNA LINC01535 via miR-214/EZH2 (76), lncRNA TP73 via miRNA-607/cyclin D2 (77), lncRNA SNHG12 via miR-125b/STAT3 (78), lncRNA ZNF667-AS1 via miRNA-93-3p-dependent PEG3 downregulation (79), lncRNA EBIC via EZH2 repressing E-cadherin (80), and lncRNA XLOC_010588 via c-Myc (81) promote cell growth, proliferation, invasion, and metastasis.

Exosomal miRNAs are involved in metabolic pathways as lncRNAs, miR-221-3p is highly expressed in CSCC and is associated with proliferation, invasion, migration and angiogenesis (82), miR-21 inactivation leads to overactivation of RAS/MAPK signaling, in consequence, the uncontrolled way leads to lymph node metastasis (83), miR-665 is downregulated in CC, its main function is the inactivation of ERK/SMAD pathway by regulating TGFBR1, its overexpression inhibits the cell cycle and drug resistance (84). Low levels of miR-138-5p are correlated with FIGO stage, poor differentiation, lymph node metastasis, and poor overall survival (OS) in CC patients (85). miR-106b is upregulated in CSCC, which is an epigenetic mechanism needed in transforming growth factor β (TGF- β)-induced cell migration (86), miR-145 modulates cell proliferation, migration and invasion by targeting SMAD interacting protein 1 (SIP1) (87), miRNA-183 is downregulated in CSCC, it acts as a tumor suppressor by inhibiting cell invasion and metastasis (88), miR-218-5p inhibits cell growth and metastasis via LYN/NF- κ B signaling pathway (89), miRNA-221-3p directly targets THBS2,

which is necessary for metastasis (90), miR-29a inhibits invasion and metastasis by modulating methylation of tumor suppressor SOCS1 (91), miR-124 represses vasculogenic mimicry and cell motility by targeting amotL1, which is a protein in charge to control endothelial migration and cell polarity, and to regulate sprouting angiogenesis (92), miR-199b-5p promotes growth and metastasis by downregulating KLK10, a tumor suppressor gene (93), miR-519d facilitates progression and metastasis by targeting SMAD7, which is necessary for the inactivation of TGF- β signaling (94), miR-543 is downregulated in CSCC, in consequence, it cannot target TRPM7, and leads to tumor growth and metastasis (95), and miRNA-21 promotes lymph node metastasis observed in an orthotopic xenograft mouse model (96). CircRNA-000284 (97) and hsa_circ_0000745 are circRNAs identified as epigenetic mechanisms in CSCC, they promote cell proliferation, migration, and invasion (98). All these epigenetic mechanisms are necessary to cervical cancer progression, and they are involucrate in many intracellular signaling pathways, as seen in Figure 2.

To understand the molecular mechanisms associated with poor prognosis and progression of CSCC, we decide to make a summary of those currently mechanisms. The importance to understand about these mechanisms is to guide investigations that could give us new targeted therapies. Nowadays, there are new clinical trials involved in treat metastatic cervical cancer, mentioned in Table 2. (99–114)

Conclusion and discussion:

Cervical cancer is the fourth most common type of cancer in women worldwide and cervical squamous cell carcinoma (CSCC) is the most aggressive subtype of cervical cancers. This is why over time new research questions have arisen to better understand the CSCC physiopathogenesis and in this way, create new therapeutic strategies. Metastasis is observed in 15-30% in cervical cancer, informed by many authors, however, its prognosis is poorer. New targeted therapies schemes have been analyzed and along, however, despite this, the prognosis is still bleak, for that reason, new clinical trials have emerged and are currently being developed in order to obtain new treatment strategies.

This article seeks to analyze and to announce, through an exhaustive review of the literature, the epigenetic mechanisms associated with metastasis reported by various authors over time and its relationship with

poor prognosis of this type of cancer. The epigenetic mechanisms are closely related between each other's and with intracellular metabolic signaling pathways. Understanding the epigenetics in metastatic CSCC will allow health professionals to establish appropriate treatment and prognosis lines for this type of cancer according to its different molecular characteristics, with the aim of reducing mortality in women with metastatic CSCC and increasing the rate of survival.

Abbreviations:

AE: Adverse Effect
 BCAR4: breast cancer anti-estrogen resistance 4
 BIRC2/3: baculoviral IAP repeat containing 2/3
 CC: cervical cancer.
 CCAT-1: colon cancer associated transcript-1
 CCNA1: cyclin A1
 CDKN2A: cyclin dependent kinase inhibitor 2A
 CI: Confidence Interval
 CircRNAs: circular RNAs
 CSCC: cervical squamous cell carcinomas
 DHX9: DExH-box helicase 9
 DM: Diabetes Mellitus
 DNMT1: DNA methyltransferase 1
 EGFR: epidermal growth factor receptor
 ELAVL2: ELAV like RNA binding protein 2
 ERBB2: erb-b2 receptor tyrosine kinase 2
 EZH2: enhancer of zeste homologue 2 gene
 FAT1: FAT atypical cadherin 1
 FIGO: International Federation of Gynecology and Obstetrics
 GAS5: growth arrest special 5
 GRB7: growth factor receptor bound protein 7
 HIF1 α : hypoxia inducible factor 1 α
 HIV: Human Immunodeficiency Virus
 HOX: Homebox
 HOTAIR: HOX transcript antisense RNA
 HPV: Human Papillomavirus
 HR: Hazzard Ratio
 HSPB1: heat shock protein family B member 1
 H3K27me3: trimethylation of lysine 27 on histone H3
 KHSRP: KH-type splicing regulatory protein
 KLF5: KLF transcription factor 5
 LncRNAs: Long non-coding RNAs
 MALAT-1: metastasis-associated lung adenocarcinoma transcript-1
 mCSCC: metastatic Cervical Squamous Cell Cancer
 MiRNAs: microRNAs
 MYC: MYC proto-oncogene

NHEJ: non-homologous end joining
 NcRNAs: non-coding RNAs
 NOVA1: neuro-oncological ventral antigen 1
 N/A: Not Applicable
 OS: overall survival
 PD-L1: programmed cell death 1 ligand
 PD-L2: programmed cell death 2 ligand
 PFS: Progression Free Survival
 PiRNAs: PIWI interacting RNAs
 PRC1: polycomb repressive complex 2
 PRC2: polycomb repressive complex 1
 PTBP1: polypyrimidine tract binding protein 1
 PTEN: phosphate and tensin homolog
 PUMA: p53 upregulated modulator of apoptosis
 RBPs: RNA-binding proteins
 RNASEH2A: ribonuclease H2A
 SIP1: SMAD interacting protein 1
 SMAD4: SMAD family member 4
 SncRNAs: small non-coding RNAs
 TGFBR2: transforming growth factor beta receptor 2
 TERC: telomerase RNA component
 TGF- β : transforming growth factor β
 TMPOP2: thymopoietin pseudogene 2
 TP63: tumor protein p63
 UCA1: urothelial cancer associated 1

Acknowledgements:

None.

Conflict of interests:

The authors declare no conflict of interests.

Funding:

None.




Figure 2. Non-coding RNAs and their signaling pathways regulation. Created with Biorender.com

Table 2. Resume of completed clinical trials and their results in metastatic Cervical Squamous Cell Cancer (mCSCC) in women of 18-64 years old, obtained by ClinicalTrials.gov

Clinical Trial	Phase	Allocation	Intervention Model	Study Start Date	Actual Study Completion Date	Experimental	Active Comparator	Median Progression Free Survival (PFS)	Median Overall Survival (OS)	Serious Adverse Effects	NCT Number	Ref
Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer	2	Randomized	Parallel Assignment	Nov, 2006	Jul, 2011	Pazopanib plus Lapatinib combination therapy	Lapatinib monotherapy and Pazopanib monotherapy	Combination therapy discontinued. Pazopanib (n=74) 18.1 weeks. Lapatinib (n=78) 17.1 weeks. HR (90% CI) 0.66 (0.48-0.91) p=0.013	Combination therapy discontinued. Pazopanib 50.7 weeks. Lapatinib 39.1 weeks. HR (90% CI) 0.67 (0.46-0.99) p=0.045	Any grade AE: Pazopanib 96% Lapatinib 92% Grade 3 AE: Pazopanib 11%, Lapatinib 13% Grade 4 AE: Pazopanib 12%, Lapatinib 9%.	NCT00430781	(99)
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)	3	Randomized	Parallel Assignment	Oct, 2018	Estimated: Jun, 2024	Pembrolizumab plus Chemotherapy (Paclitaxel, cisplatin, carboplatin, and bevacizumab)	Placebo plus Chemotherapy (Paclitaxel, cisplatin, carboplatin, and bevacizumab)	Pembrolizumab group 10.4 months, HR 0.58 (95% CI, 0.44-0.77) p<0.001	Pembrolizumab group 24 months, HR 0.61 (95% CI, 0.44-0.84) p=0.001	Any grade AE: Pembrolizumab group 99.3% Placebo group 99.4% Grade 3-5 AE: Pembrolizumab group 81.8% Placebo group 75.1%	NCT03635567	(100)
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer	2	N/A	Single Group Assignment	March, 2017	Jan, 2021	Atezolizumab plus Bevacizumab combination therapy	N/A	Combination therapy 2.9 months (95% CI, 1.8-6).	Combination therapy 8.9 months (95% CI, 3.4-21.9)	Any grade AE: 100% Serious EA: 0%	NCT02921269	(101)
Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study	2	N/A	Single Group Assignment	Jan, 2003	March, 2010	Oxaliplatin plus Paclitaxel	N/A	Combination therapy (Total of 135 cycles) 21 weeks (95% CI, 14.7-27.2)	Combination therapy (Total of 135 cycles) 52 weeks (95% CI, 39.4-64.8)	Any grade AE: 100% Serious AE: 100%	NCT00057863	(102)
Phase II Evaluation of Nivolumab in the Treatment of Persistent or Recurrent Cervical Cancer (NCT02257528/NRG-GY002)	2	N/A	Single Group Assignment	May, 2015	March, 2019	Nivolumab	N/A	Nivolumab 3.5 months (90% CI, 1.9-5.1)	Nivolumab 14.5 months (90% CI, 8.3-26.8)	Any grade AE: 96% Serious AE: 48%	NCT02257528	(103)

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/ GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study	2	N/A	Single Group Assignment	June, 2018	Aug, 2022	Tisotumab vedotin	N/A	Tisotumab vedotin 4.2 months (95% CI, 3-4.4)	Tisotumab vedotin 12.1 months (95% CI, 9.6-13.9)	Any grade AE: 98.02% Serious AE: 43.56%	NCT03438396	(104)
Continued.												
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer	3	Randomized	Parallel assignment	Sept, 2017	Apr, 2023	Cemiplimab	Topotecan or irinotecan, gemcitabine, vinorelbine plus pemetrexed	Cemiplimab group 2.8 months (95% CI, 2.6-3.9) Chemotherapy group 2.9 months (95% CI, 2.7-3.4) HR for disease progression or death 0.75 (95% CI, 0.63-0.89) p<0.001	Cemiplimab group 12 months (95% CI, 10.3-13.5) Chemotherapy group 8.5 months (95% CI, 7.5-9.6)	Any grade AE: Cemiplimab group 87.67% Chemotherapy group 91.03% Serious AE: Cemiplimab group 30.33% Chemotherapy group 27.93%	NCT03257267	(105, 106)
Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors	2	Non-Randomized	Parallel assignment	Feb, 2018	Dec, 2021	Simlukafusp alfa plus atezolizumab	N/A	Cohort J (n=44): 3.7 months (95% CI, 3.3-9) Cohort N (n=1): 1.9 months (95% CI, N/A to N/A)	Cohort J (n=44): N/A Cohort N (n=1): N/A	Any grade AE: Cohort J: 100% Cohort N: 100% Serious AE: Cohort J: 68.09% Cohort N: 100%	NCT03386721	(107)
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy	2	N/A	Single Group Assignment	Aug, 2009	Sept, 2011	Zalypsis (PM00104)	N/A	Zalypsis 1.5 months (95% CI, 1.5-1.8)	Zalypsis 5.6 months (95% CI, N/A – N/A)	Any grade AE: 100% Serious AE: 42.86%	NCT00900562	(108)
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer	2	N/A	Single Group Assignment	Dec, 2012	Nov, 2021	Ipilimumab	N/A	Ipilimumab 2.5 months (95% CI, 2-3.2)	Not mentioned	Any grade AE: 100% Serious AE: 59.52%	NCT01693783	(109)

A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study	1	N/A	Single Group Assignment	Nov, 1999	Jul, 2009	Cisplatin, paclitaxel, brachytherapy plus radiation therapy	N/A	Probability of Disease-Free Survival at 2 years 0.65 (95% CI, 0.44-0.86)	Probability of Overall Survival at 2 years 0.80 (95% CI, 0.62-0.97)	Any grade AE: Arm 1, 2 and 3 P I: 100% Arm 4 P I: 66.67% Arm 2 P II: 88.24% Serious AE: Arm 3, P I: 33.33% Arm 4, P I: 66.67% Arm 2, P II: 5.88%	NCT00003377	(110)
Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus-Targeted Tumor-Infiltrating T Cells	2	Non-Randomized	Parallel Assignment	Apr, 2012	Aug, 2016	Fludarabine, cyclophosphamide, Young TIL plus aldesleukin	N/A	Overall number of participants: 18 Partial response: 3 (16.7%) Complete response: 2 (11.1%) Progressive disease: 12 (66.7%) Stable disease: 1 (5.6%)		Any grade AE: 94.44% Serious AE: 22.22%	NCT01585428	(111)
Continued												
Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial	2	Non-Randomized	Single Group Assignment	Dec, 2019	Dec, 2022	Sintilimab plus anlotinib	N/A	Median PFS 9.4 months (95% CI, 8-14.6) 6-month PFS 73.1% (95% CI, 60.1-88.9%)	OS events occurred in 10 patients (23.8%). Median OS was not reached. 12-month OS rate was 73.8% (95% CI, 59.3-91.7%)	Any grade AE: 85.8% Serious AE: 16.7%	Not mentioned	(112)
Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery	2	N/A	Single Group Assignment	Jan, 2007	Marc, 2009	Sunitinib malate	N/A	Objective Response Rate (n=19): 0 (95% CI, 0.1-7.6)		Any grade AE: 100% Serious AE:73.68%	NCT00389974	(113)
Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery	2	N/A	Single Group Assignment	Dec, 2009	Nov, 2012	Temsirolimus	N/A	Objective Response Rate (n=33): 3 (95% CI, 0.1-15.8)		Any grade AE: 100% Serious AE: 40.54%	NCT01026792	(114)

References:

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3):209–49.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah K V, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide [Internet]. [cited 2023 Oct 28]. Available from: <https://pubmed.ncbi.nlm.nih.gov/10451482/>
3. Su B, Qin W, Xue F, Wei X, Guan Q, Jiang W, et al. The relation of passive smoking with cervical cancer: A systematic review and meta-analysis. *Medicine.* 2018 Nov 1;97(46).
4. Kyrgiou M, Arbyn M, Bergeron C, Bosch FX, Dillner J, Jit M, et al. Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). *Br J Cancer.* 2020 Aug 18;123(4):510–7.
5. Moscicki AB, Flowers L, Huchko MJ, Long ME, MacLaughlin KL, Murphy J, et al. Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection. *J Low Genit Tract Dis.* 2019 Apr 1;23(2):87–101.
6. Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of the global burden of cervical cancer associated with HIV. *Lancet Glob Health.* 2021 Feb 1;9(2):e161–9.
7. Aballéa S, Beck E, Cheng X, Demarteau N, Li X, Ma F, et al. Risk factors for cervical cancer in women in China: A meta-model. *Womens Health (Lond).* 2020;16.
8. Li X, Hu SY, He Y, Hernandez Donoso L, Qu KQ, Van Kriekinge G, et al. Systematic literature review of risk factors for cervical cancer in the Chinese population. *Women's Health.* 2018;14.
9. McBride AA, Warburton A. The role of integration in oncogenic progression of HPV-associated cancers. *PLoS Pathog.* 2017;13(4):1–7.
10. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylva B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. *Virus Genes.* 2010;40(1):1–13.
11. Li X, Tian R, Gao H, Yang Y, Williams BRG, Gantier MP, et al. Identification of a histone family gene signature for predicting the prognosis of cervical cancer patients. *Sci Rep.* 2017;7(1):1–13.
12. Roos D, Blood I, Immunol H. P53 Primary Human-Papillomavirus-Negative. 1990;(D):1070–3.
13. Brant AC, Menezes AN, Felix SP, de Almeida LM, Sammeth M, Moreira MAM. Characterization of HPV integration, viral gene expression and E6E7 alternative transcripts by RNA-Seq: A descriptive study in invasive cervical cancer. *Genomics.* 2019;111(6):1853–61.
14. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. *EMBO Journal.* 1991;10(13):4129–35.
15. Zimmermann H, Degenkolbe R, Bernard HU, O'Connor MJ. The Human Papillomavirus Type 16 E6 Oncoprotein Can Down-Regulate p53 Activity by Targeting the Transcriptional Coactivator CBP/p300. *J Virol.* 1999;73(8):6209–19.
16. Nakamura M, Obata T, Daikoku T, Fujiwara H. The association and significance of p53 in gynecologic cancers: The potential of targeted therapy. *Int J Mol Sci.* 2019;20(21):1–16.
17. Yeung CLA, Tsang WP, Tsang TY, Co NN, Yau PL, Kwok TT. HPV-16 E6 upregulation of DNMT1 through repression of tumor suppressor p53. *Oncol Rep.* 2010;23(3):861–7.
18. Sartor MA, Dolinoy DC, Jones TR, Colacino JA, Prince MEP, Carey TE, et al. Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. *Epigenetics.* 2011;6(6):777–87.
19. Chalertpet K, Pakdechaidan W, Patel V, Mutirangura A, Yanatatsaneejit P. Human papillomavirus type 16 E7 oncoprotein mediates CCNA1 promoter methylation. *Cancer Sci.* 2015;106(10):1333–40.

20. Menges CW, Baglia LA, Lapoint R, McCance DJ. Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein. *Cancer Res.* 2006;66(11):5555–9.
21. Münger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. *EMBO J.* 1989;8(13):4099–105.
22. D'Costa ZJ, Jolly C, Androphy EJ, Mercer A, Matthews CM, Hibma MH. Transcriptional Repression of E-Cadherin by Human Papillomavirus Type 16 E6. *PLoS One.* 2012;7(11).
23. Caberg JH, Hubert P, Herman L, Herfs M, Roncarati P, Boniver J, et al. Increased migration of Langerhans cells in response to HPV16 E6 and E7 oncogene silencing: Role of CCL20. *Cancer Immunology, Immunotherapy.* 2009;58(1):39–47.
24. Giannini SL, Hubert P, Doyen J, Boniver J, Delvenne P. Influence of the mucosal epithelium microenvironment on Langerhans cells: Implications for the development of squamous intraepithelial lesions of the cervix. *Int J Cancer.* 2002;97(5):654–9.
25. Laurson J, Khan S, Chung R, Cross K, Raj K. Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. *Carcinogenesis.* 2010;31(5):918–26.
26. Burgers WA, Blanchon L, Pradhan S, De Launoit Y, Kouzarides T, Fuks F. Viral oncoproteins target the DNA methyltransferases. *Oncogene.* 2007;26(11):1650–5.
27. Yang N, Nijhuis ER, Volders HH, Eijssink JJH, Lendvai Á, Zhang B, et al. Gene promoter methylation patterns throughout the process of cervical carcinogenesis. *Cellular Oncology.* 2010;32(1–2):131–43.
28. Lechner M, Fenton T, West J, Wilson G, Feber A, Henderson S, et al. Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma. *Genome Med.* 2013;5(2):1–16.
29. Holland D, Hoppe-Seyler K, Schuller B, Lohrey C, Maroldt J, Dürst M, et al. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. *Cancer Res.* 2008;68(23):9964–72.
30. Hyland PL, McDade SS, McCloskey R, Dickson GJ, Arthur K, McCance DJ, et al. Evidence for Alteration of EZH2, BMI1, and KDM6A and Epigenetic Reprogramming in Human Papillomavirus Type 16 E6/E7-Expressing Keratinocytes. *J Virol.* 2011;85(21):10999–1006.
31. McLaughlin-Drubin ME, Crum CP, Münger K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. *Proc Natl Acad Sci U S A.* 2011;108(5):2130–5.
32. McLaughlin-Drubin ME, Huh KW, Münger K. Human Papillomavirus Type 16 E7 Oncoprotein Associates with E2F6. *J Virol.* 2008;82(17):8695–705.
33. Xu J, Liu H, Yang Y, Wang X, Liu P, Li Y, et al. Genome-Wide Profiling of Cervical RNA-Binding Proteins Identifies Human Papillomavirus Regulation of RNASEH2A Expression by Viral E7 and E2F1. *American Society for Microbiology.* 2019;10(1):1–16.
34. Burk RD, Chen Z, Saller C, Tarvin K, Carvalho AL, Scapulatempo-Neto C, et al. Integrated genomic and molecular characterization of cervical cancer. *Nature.* 2017;543(7645):378–84.
35. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in *Caenorhabditis elegans*. *Science* (1979). 2001 Oct 26;294(5543):858–62.
36. Vos PD, Leedman PJ, Filipovska A, Rackham O. Modulation of miRNA function by natural and synthetic RNA-binding proteins in cancer. *Cellular and Molecular Life Sciences.* 2019 Oct 1;76(19):3745–52.
37. Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. *Nucleic Acids Res.* 2019 Jan 8;47(D1):D155–62.
38. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. *Rna.* 2013;19(2):141–57.
39. Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et

- al. Exon-intron circular RNAs regulate transcription in the nucleus. *Nat Struct Mol Biol.* 2015;22(3):256–64.
40. Zeng Q, Wan H, Zhao S, Xu H, Tang T, Oware KA, et al. Role of PIWI-interacting RNAs on cell survival: Proliferation, apoptosis, and cycle. *IUBMB Life.* 2020 Sep 1;72(9):1870–8.
41. Ding X, Jia X, Wang C, Xu J, Gao SJ, Lu C. A DHX9-lncRNA-MDM2 interaction regulates cell invasion and angiogenesis of cervical cancer. *Cell Death Differ.* 2019;26(9):1750–65.
42. Su K, Zhao Q, Bian A, Wang C, Cai Y, Zhang Y. A novel positive feedback regulation between long noncoding RNA UICC and IL-6/STAT3 signaling promotes cervical cancer progression. *Am J Cancer Res.* 2018;8(7):1176–89.
43. Zhang J, Gao Y. CCAT-1 promotes proliferation and inhibits apoptosis of cervical cancer cells via the Wnt signaling pathway. *Oncotarget.* 2017;8(40):68059–70.
44. Liu Y, Chang Y, Lu S, Xiang YY. Downregulation of long noncoding RNA DGCR5 contributes to the proliferation, migration, and invasion of cervical cancer by activating Wnt signaling pathway. *J Cell Physiol.* 2019;234(7):11662–9.
45. Zhu L, Zhang Q, Li S, Jiang S, Cui J, Dang G. Interference of the long noncoding RNA CDKN2B-AS1 upregulates miR-181a-5p/TGF β I axis to restrain the metastasis and promote apoptosis and senescence of cervical cancer cells. *Cancer Med.* 2019;8(4):1721–30.
46. Sun R, Qin C, Jiang B, Fang S, Pan X, Peng L, et al. Down-regulation of MALAT1 inhibits cervical cancer cell invasion and metastasis by inhibition of epithelial-mesenchymal transition. *Mol Biosyst.* 2016;12(3):952–62.
47. Shen F, Zheng H, Zhou L, Li W, Xu X. Overexpression of MALAT1 contributes to cervical cancer progression by acting as a sponge of miR-429. *J Cell Physiol.* 2019;234(7):11219–26.
48. Han X, Wang Q, Wang Y, Hu B, Dong X, Zhang H, et al. Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1/microRNA-202-3p/periostin axis modulates invasion and epithelial–mesenchymal transition in human cervical cancer. *J Cell Physiol.* 2019;234(8):14170–80.
49. H H, Liu X, Liu Y, Zhang M, Lai Y, Hao Y, et al. Human Papillomavirus E6/E7 and Long Noncoding RNA TMPOP2 Mutually Upregulated Gene Expression in Cervical Cancer Cells. 2019;93(8):1–14.
50. Wang X, Liu H, Shi L, Yu X, Gu Y, Sun X. LINP1 facilitates DNA damage repair through non-homologous end joining (NHEJ) pathway and subsequently decreases the sensitivity of cervical cancer cells to ionizing radiation. *Cell Cycle.* 2018;17(4):439–47.
51. Fan L, Huang C, Li J, Gao T, Lin Z, Yao T. Long non-coding RNA urothelial cancer associated 1 regulates radioresistance via the hexokinase 2/glycolytic pathway in cervical cancer. *Int J Mol Med.* 2018;42(4):1875–84.
52. Zhao H, Zheng GH, Li GC, Xin L, Wang YS, Chen Y, et al. Long noncoding RNA LINC00958 regulates cell sensitivity to radiotherapy through RRM2 by binding to microRNA-5095 in cervical cancer. *J Cell Physiol.* 2019;234(12):23349–59.
53. Yang W, Hong L, Xu X, Wang Q, Huang J, Jiang L. LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205. *Tumor Biology.* 2017;39(7):1–10.
54. Wang X, Zhang J, Wang Y. Long noncoding RNA GAS5-AS1 suppresses growth and metastasis of cervical cancer by increasing GAS5 stability. *Am J Transl Res.* 2019;11(8):4909–21.
55. Wang Q, Ding J, Nan G, Lyu Y, Ni G. LncRNA NOC2L-4.1 functions as a tumor oncogene in cervical cancer progression by regulating the miR-630/YAP1 pathway. *J Cell Biochem.* 2019;120(10):16913–20.
56. Xiang S, Gu H, Jin L, Thorne RF, Zhang XD, Wu M. LncRNA IDH1-AS1 links the functions of c-Myc and HIF1 α via IDH1 to regulate the Warburg effect. *Proc Natl Acad Sci U S A.* 2018;115(7):E1465–74.
57. Shen CJ, Cheng YM, Wang CL. LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells. *J Drug Target.* 2017;25(7):637–44.

58. Zhang S, Zhang G, Liu J. Long noncoding RNA PVT1 promotes cervical cancer progression through epigenetically silencing miR-200b. *Apmis*. 2016;124(8):649–58.
59. Shao S, Wang C, Wang S, Zhang H, Zhang Y. LncRNA STXBP5-AS1 suppressed cervical cancer progression via targeting miR-96-5p/PTEN axis. *Biomedicine and Pharmacotherapy*. 2019;117(May):109082.
60. Xu J, Zhang J. LncRNA TP73-AS1 is a novel regulator in cervical cancer via miR-329-3p/ARF1 axis. *J Cell Biochem*. 2020;121(1):344–52.
61. Zhu Y, Liu B, Zhang P, Zhang J, Wang L. LncRNA TUSC8 inhibits the invasion and migration of cervical cancer cells via miR-641/PTEN axis. *Cell Biol Int*. 2019;43(7):781–8.
62. Zhu H, Zheng T, Yu J, Zhou L, Wang L. LncRNA XIST accelerates cervical cancer progression via upregulating Fus through competitively binding with miR-200a. *Biomedicine and Pharmacotherapy*. 2018;105(March):789–97.
63. Cheng YX, Zhang QF, Hong L, Pan F, Huang JL, Li BS, et al. MicroRNA-200b suppresses cell invasion and metastasis by inhibiting the epithelial-mesenchymal transition in cervical carcinoma. *Mol Med Rep*. 2016;13(4):3155–60.
64. Luan X, Wang Y. LncRNA XLOC_006390 facilitates cervical cancer tumorigenesis and metastasis as a ceRNA against miR-331-3p and miR-338-3p. *J Gynecol Oncol*. 2018;29(6):1–17.
65. Feng S, Liu W, Bai X, Pan W, Jia Z, Zhang S, et al. LncRNA-CTS promotes metastasis and epithelial-to-mesenchymal transition through regulating miR-505/ZEB2 axis in cervical cancer. *Cancer Lett*. 2019;465(August):105–17.
66. Zhu Y, Wu Y, Yang L, Dou X, Jiang J, Wang L. Long non-coding RNA activated by transforming growth factor- β promotes proliferation and invasion of cervical cancer cells by regulating the miR-144/ITGA6 axis. *Exp Physiol*. 2019;104(6):837–44.
67. Zhang D, Sun G, Zhang H, Tian J, Li Y. Long non-coding RNA ANRIL indicates a poor prognosis of cervical cancer and promotes carcinogenesis via PI3K/Akt pathways. *Biomedicine and Pharmacotherapy*. 2017;85:511–6.
68. Zhang JJ, Fan LP. Long non-coding RNA CRNDE enhances cervical cancer progression by suppressing PUMA expression. *Biomedicine and Pharmacotherapy*. 2019;117(December 2018):108726.
69. Zhang Y, Cheng X, Liang H, Jin Z. Long non-coding RNA HOTAIR and STAT3 synergistically regulate the cervical cancer cell migration and invasion. *Chem Biol Interact*. 2018;286(January):106–10.
70. Sun J, Chu H, Ji J, Huo G, Song Q, Zhang X. Long non-coding RNA HOTAIR modulates HLA-G expression by absorbing miR-148a in human cervical cancer. *Int J Oncol*. 2016;49(3):943–52.
71. Zhang J, Gao Y. Long non-coding RNA MEG3 inhibits cervical cancer cell growth by promoting degradation of P-STAT3 protein via ubiquitination. *Cancer Cell Int*. 2019;19(1):1–10.
72. Fan MJ, Zou YH, He PJ, Zhang S, Sun XM, Li CZ. Long non-coding RNA SPRY4-IT1 promotes epithelial-mesenchymal transition of cervical cancer by regulating the miR-101-3p/ZEB1 axis. *Biosci Rep*. 2019;39(6):1–11.
73. Chen P, Wang R, Yue Q, Hao M. Long non-coding RNA TTN-AS1 promotes cell growth and metastasis in cervical cancer via miR-573/E2F3. *Biochem Biophys Res Commun*. 2018;503(4):2956–62.
74. Zhu J, Shi H, Liu H, Wang X, Li F. Long non-coding RNA TUG1 promotes cervical cancer progression by regulating the miR-138-5p-SIRT1 axis. *Oncotarget*. 2017;8(39):65253–64.
75. Cheng R, Li N, Yang S, Liu L, Han S. Long non-coding RNA ZEB1-AS1 promotes cell invasion and epithelial to mesenchymal transition through inducing ZEB1 expression in cervical cancer. *Onco Targets Ther*. 2018;11:7245–53.
76. Song H, Liu Y, Jin X, Liu Y, Yang Y, Li L, et al. Long non-coding RNA LINC01535 promotes cervical cancer progression via targeting the miR-214/EZH2 feedback loop. *J Cell Mol Med*. 2019;23(9):6098–111.
77. Zhang H, Xue B, Wang S, Li X, Fan T. Long non-coding RNA TP73 antisense RNA 1 facilitates

- the proliferation and migration of cervical cancer cells via regulating microRNA-607/cyclin D2. *Mol Med Rep.* 2019;20(4):3371–8.
78. Jin XJ, Chen XJ, Zhang ZF, Hu WS, Ou RY, Li S, et al. Long noncoding RNA SNHG12 promotes the progression of cervical cancer via modulating miR-125b/STAT3 axis. *J Cell Physiol.* 2019;234(5):6624–32.
79. Li YJ, Yang Z, Wang YY, Wang Y. Long non-coding RNA ZNF667-AS1 reduces tumor invasion and metastasis in cervical cancer by counteracting microRNA-93-3p-dependent PEG3 downregulation. *Mol Oncol.* 2019;13(11):2375–92.
80. Sun NX, Ye C, Zhao Q, Zhang Q, Xu C, Wang SB, et al. Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing E-cadherin in cervical cancer. *PLoS One.* 2014;9(7):1–9.
81. Liao LM, Sun XY, Liu AW, Wu JB, Cheng XL, Lin JX, et al. Low expression of long noncoding XLOC-010588 indicates a poor prognosis and promotes proliferation through upregulation of c-Myc in cervical cancer. *Gynecol Oncol.* 2014;133(3):616–23.
82. Zhang L, Li H, Yuan M, Li M, Zhang S. Cervical cancer cells-secreted exosomal microRNA-221-3p promotes invasion, migration and angiogenesis of microvascular endothelial cells in cervical cancer by down-regulating MAPK10 expression. *Cancer Manag Res.* 2019;11:10307–19.
83. Zhang L, Zhan X, Yan D, Wang Z. Circulating MicroRNA-21 Is Involved in Lymph Node Metastasis in Cervical Cancer by Targeting RASA1. *International Journal of Gynecological Cancer.* 2016;26(5):810–6.
84. Cao L, Jin H, Zheng Y, Mao Y, Fu Z, Li X, et al. DANCER-mediated microRNA-665 regulates proliferation and metastasis of cervical cancer through the ERK/SMAD pathway. *Cancer Sci.* 2019;110(3):913–25.
85. Ou L, Wang D, Zhang H, Yu Q, Hua F. Decreased expression of miR-138-5p by lncRNA H19 in cervical cancer promotes tumor proliferation. *Oncol Res.* 2018;26(3):401–10.
86. Cheng Y, Guo Y, Zhang Y, You K, Li Z, Geng L. MicroRNA-106b is involved in transforming growth factor β 1-induced cell migration by targeting disabled homolog 2 in cervical carcinoma. *Journal of Experimental and Clinical Cancer Research.* 2016;35(1):1–11.
87. Sathyanarayanan A, Chandrasekaran KS, Karunakaran D. microRNA-145 modulates epithelial-mesenchymal transition and suppresses proliferation, migration and invasion by targeting SIP1 in human cervical cancer cells. *Cellular Oncology.* 2017;40(2):119–31.
88. Fan D, Wang Y, Qi P, Chen Y, Xu P, Yang X, et al. MicroRNA-183 functions as the tumor suppressor via inhibiting cellular invasion and metastasis by targeting MMP-9 in cervical cancer. *Gynecol Oncol.* 2016;141(1):166–74.
89. Xu Y, He Q, Lu Y, Tao F, Zhao L, Ou R. MicroRNA-218-5p inhibits cell growth and metastasis in cervical cancer via LYN/NF- κ B signaling pathway. *Cancer Cell Int.* 2018;18(1):1–15.
90. Wei WF, Zhou CF, Wu XG, He LN, Wu LF, Chen XJ, et al. MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2 article. *Cell Death Dis.* 2017;8(12).
91. Gong Y, Wan JH, Zou W, Lian GY, Qin JL, Wang QM. MiR-29a inhibits invasion and metastasis of cervical cancer via modulating methylation of tumor suppressor SOCS1. *Future Oncology.* 2019;15(15):1729–44.
92. Wan HY, Li QQ, Zhang Y, Tian W, Li YN, Liu M, et al. MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells. *Cancer Lett.* 2014;355(1):148–58.
93. Xu LJ, Duan Y, Wang P, Yin HQ. MiR-199b-5p promotes tumor growth and metastasis in cervical cancer by down-regulating KLK10. *Biochem Biophys Res Commun.* 2018;503(2):556–63.
94. Zhou JY, Zheng SR, Liu J, Shi R, Yu HL, Wei M. MiR-519d facilitates the progression and metastasis of cervical cancer through direct targeting Smad7.

Cancer Cell Int. 2016;16(1):1–12.

95. Liu X, Gan L, Zhang J. miR-543 inhibites cervical cancer growth and metastasis by targeting TRPM7. *Chem Biol Interact.* 2019;302:83–92.
96. Wei WF, Han LF, Liu D, Wu LF, Chen XJ, Yi HY, et al. Orthotopic xenograft mouse model of cervical cancer for studying the role of MicroRNA-21 in promoting lymph node metastasis. *International Journal of Gynecological Cancer.* 2017;27(8):1587–95.
97. Han-Bo M, Yi-Nan Y, Jin-Jun Y, Xue-Xue C, Huai-Fang L. Extensive profiling of circular RNAs and the potential regulatory role of circRNA-000284 in cell proliferation and invasion of cervical cancer via sponging miR-506. *Am J Transl Res.* 2018;10(2):592–604.
98. Jiao J, Zhang T, Jiao X, Huang T, Zhao L, Ma D, et al. Hsa_Circ_0000745 Promotes Cervical Cancer By Increasing Cell Proliferation, Migration, and Invasion. *J Cell Physiol.* 2020;235(2):1287–95.
99. Monk BJ, Lopez LM, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. *Journal of Clinical Oncology.* 2010;28(22):3562–9.
100. Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. Vol. 77, *Obstetrical and Gynecological Survey.* 2022. p. 30–1.
101. Friedman CF, Snyder Charen A, Zhou Q, Carducci MA, Buckley De Meritens A, Corr BR, et al. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. *J Immunother Cancer.* 2020;8(2):1–10.
102. Kuo DYS, Blank S V., Christos PJ, Kim M, Caputo TA, Pothuri B, et al. Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: A New York Cancer Consortium Study. *Gynecol Oncol.* 2010;116(3):442–6.
103. Sweatt, S.K., Gower, B.A., Chieh, A.Y., Liu, Y, Li L. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). *Physiol Behav.* 2016;176(1):139–48.
104. Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol.* 2021;22(5):609–19.
105. Tewari KS, Monk BJ, Vergote I, Miller A. Survival with Cemiplimab in Recurrent Cervical Cancer | Enhanced Reader. 2022. p. 544–55.
106. Oaknin A, Monk BJ, Vergote I, Cristina de Melo A, Kim YM, Lisysanskaya AS, et al. EMPOWER CER-VICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer. *Eur J Cancer.* 2022;174:299–309.
107. Hoffmann-La Roche. Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors - Study Results - ClinicalTrials.gov [Internet]. [cited 2023 Oct 19]. Available from: <https://classic.clinicaltrials.gov/ct2/show/results/NCT03386721?rslt=With&type=Intr&cond=Metastatic+Cervical+Cancer&gndr=Female&age=1&draw=2&rank=10>
108. PharmaMar S.A. Results Posted | Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy | ClinicalTrials.gov [Internet]. 2021 [cited 2023 Oct 19]. Available from: <https://clinicaltrials.gov/study/NCT00900562?tab=results#adverse-events>
109. Institute NC. Results Posted | Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer | ClinicalTrials.gov [Internet]. 2022 [cited 2023 Oct 19]. Available from: <https://clinicaltrials.gov/study/>

NCT01693783?tab=results#adverse-events

110. Walker JL, Morrison A, DiSilvestro P, Gruenigen VE von, Group GO. A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study. *Gynecologic Oncology Group*. 2015;112(1):78–84.

111. Stevanović S, Draper LM, Langan MM, Campbell TE, Kwong ML, Wunderlich JR, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. *Journal of Clinical Oncology*. 2015;33(14):1543–50.

112. Xu Q, Wang J, Sun Y, Lin Y, Liu J, Zhuo Y, et al. Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial. *Journal of Clinical Oncology*. 2022;40(16):1795–806.

113. Institute NC. Results Posted | Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery | ClinicalTrials.gov [Internet]. 2015 [cited 2023 Oct 19]. Available from: <https://clinicaltrials.gov/study/NCT00389974?tab=results#adverse-events>

114. Institute NC. Results Posted | Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery | ClinicalTrials.gov [Internet]. 2015 [cited 2023 Oct 19]. Available from: <https://clinicaltrials.gov/study/NCT01026792?tab=results#outcome-measures>